NCT00775671
Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome
See it on ClinicalTrials.gov ↗46 people
65.2%
34.8%
30 womenmiddle line = equal numbers16 men
- Phase
- PHASE4
- Paid for by
- Vanderbilt University
- Finished
- 2011-06
- Health conditions
- Metabolic Syndrome
- Who could join
- Anyone
- Ages
- 18 Years – 70 Years
- Average age
- mean 44.4 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnancy”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Breast-feeding”
- Had to use birth control
Women who couldn't or didn't want to use birth control were turned away.
“if of childbearing potential, utilization of adequate birth control and willingness to undergo urine beta-hcg testing prior to drug treatment and on every study day”
- No hormone therapy
Women taking menopause hormones or gender-affirming hormones could not join.
“Use of hormone replacement therapy”
- Only women past menopause
Women who could still get pregnant were turned away.
“postmenopausal status for at least 1 year, or”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, s…”
- No diabetes
Women with diabetes were turned away.
“Diabetes type 1 or type 2, as defined by a fasting glucose of 126 mg/dL or greater or the use of anti-diabetic medication”
Study titles and rules are shown in their original English.